De Ruysscher Dirk, Granton Patrick Vincent, Lieuwes Natasja Gaby, van Hoof Stefan, Wollin Lutz, Weynand Birgit, Dingemans Anne-Marie, Verhaegen Frank, Dubois Ludwig
Department of Radiation Oncology (Maastro), GROW - School for Oncology and Developmental Biology, Maastricht University Medical Center, The Netherlands; Department of Radiation Oncology, KU Leuven, Belgium.
Department of Radiation Oncology (Maastro), GROW - School for Oncology and Developmental Biology, Maastricht University Medical Center, The Netherlands.
Radiother Oncol. 2017 Sep;124(3):482-487. doi: 10.1016/j.radonc.2017.07.014. Epub 2017 Jul 31.
Nintedanib has anti-fibrotic and anti-inflammatory activity and is approved for the treatment of idiopathic pulmonary fibrosis. The aim of this study was to noninvasively assess the efficacy of nintedanib in a mouse model of partial lung irradiation to prevent radiation-induced lung damage (RILD).
266 C57BL/6 adult male mice were irradiated with a single radiation dose (0, 4, 8, 12, 16 or 20Gy) using parallel-opposed fields targeting the upper right lung using a precision image-guided small animal irradiator sparing heart and spine based on micro-CT images. One week post irradiation, mice were randomized across nintedanib daily oral gavage treatment (0, 30 or 60mg/kg). CT density analysis of the lungs was performed on monthly acquired micro-CT images. After 39weeks, lungs were processed to evaluate the fibrotic phenotype.
Although the CT density increase correlated with the radiation dose, nintedanib did not influence this relationship. Immunohistochemical analysis confirmed the ability of nintedanib to reduce the microscopic fibrotic phenotype, in particular interstitial edema, interstitial and perivascular fibrosis and inflammation, and vasculitis.
Nintedanib reduces radiation-induced lung fibrosis after partial lung irradiation without adverse effects, however, noninvasive CT imaging measuring electron density cannot be applied for monitoring its effects.
尼达尼布具有抗纤维化和抗炎活性,已被批准用于治疗特发性肺纤维化。本研究的目的是在部分肺照射的小鼠模型中无创评估尼达尼布预防放射性肺损伤(RILD)的疗效。
使用精确图像引导的小动物辐照仪,基于微型计算机断层扫描(micro-CT)图像,采用平行相对野,以右上肺为靶区,对266只C57BL/6成年雄性小鼠进行单次辐射剂量(0、4、8、12、16或20Gy)照射,同时保护心脏和脊柱。照射后1周,将小鼠随机分为尼达尼布每日口服灌胃治疗组(0、30或60mg/kg)。每月获取的微型计算机断层扫描图像对肺部进行CT密度分析。39周后,对肺部进行处理以评估纤维化表型。
尽管CT密度增加与辐射剂量相关,但尼达尼布并未影响这种关系。免疫组织化学分析证实尼达尼布能够减轻微观纤维化表型,特别是间质性水肿、间质和血管周围纤维化及炎症,以及血管炎。
尼达尼布可减轻部分肺照射后的放射性肺纤维化且无不良反应,然而,测量电子密度的无创CT成像不能用于监测其效果。